复星医药子公司地舒单抗生物类似药HLX14药品注册申请获受理

Core Viewpoint - Fosun Pharma's subsidiary Shanghai Fuhong Hanlin Biotech has received acceptance for its drug registration application for HLX14, a biosimilar to Prolia, from the National Medical Products Administration of China [1] Group 1 - The drug HLX14 is a recombinant anti-RANKL fully human monoclonal antibody injection [1] - The application is for all indications that Prolia has been approved for in China [1]